Vinpocetine is a modified compound originally found in the periwinkle plant (Vinca minor) that helps support brain function and cognitive health. Like the well-known botanical, Ginkgo biloba, vinpocetine supports blood flow, oxygen and nutrient delivery to the brain; unlike ginkgo, it does so without reducing blood flow elsewhere in the body. Studies in red blood cells and damaged neurons show that vinpocetine directly increases ATP levels in these cells, supporting optimal brain energy levels. In addition, vinpocetine’s blood thinning effects are far less potent than those of ginkgo, making it a much safer compound. One study showed that vinpocetine helped reduce tinnitus and hearing loss after exposure to loud noises, and research suggests that it may also enhance circulation in the eyes.
Vinpo-15 is an excellent alternative for those who want the health benefits of Ginkgo biloba, but who are concerned about its blood thinning effects. Vinpo-15 is a good choice for those looking to support their memory and brain function with age, as well as those with a family history of stroke. Vinpo-15 may also improve eye health and tinnitus.
AOR’s Vinpo-15 delivers a clinically effective dose of vinpocetine to help improve brain function.
Vinpo-15 is vinpocetine a compound found in Voacanga Africana. Vinpocetine helps support brain function and cognitive health.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by-product.
Take one capsule three times daily with food, or as directed by a qualified health care practitioner.
Do not take if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you are taking blood thinners, if you have high or low blood pressure, cardiac arrhythmia, dementia, or have suffered a stroke. Hypersensitivity is known to occur, and some people may experience anxiety, gastrointestinal discomfort, dizziness or headaches, in which case, discontinue use.
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: microcrystalline cellulose, sodium stearyl fumarate. Capsule: hypromellose.
Stroke Deficits and Dementia
Many clinical trials have demonstrated Vinpocetine’s ability to support brain function. Most of these trials have been performed in stroke victims, but research also supports Vinpocetine’s positive impact on cognitive function in organic dementias and in normal, healthy adults.
A meta-analysis of seven double-blind clinical trials involving a total of 731 people suffering from age-related dementias or cognitive deficits following a stroke found that Vinpocetine improved cognitive and neurological function on a wide variety of measures, including scores tests of memory and mental function like the Sandoz Clinical Assessment-Geriatric (SCAG) and the Mini-Mental Status Questionnaire (MMSQ), neurological symptoms such as coordination and repetitive speaking patters (palilalia), and overall functional status as evaluated using the Clinical Global Impression (CGI) scale. Furthermore, there were no serious side effects related to Vinpocetine use. Overall, the investigators concluded, the results of these trials prove that patient users of Vinpocetine “become more vivid, the cognitive performance improves, and the daily activity is more intense.”
Reduced Cerebral Blood Flow
One recent long-term observational study examined the safety of 30 mg oral vinpocetine per day for 90 days on 4865 patients with chronic cereobrovascular insufficiency with arterial hypertension. The dose was well tolerated, and their neurological symptoms improved as did their MMSE (mini-mental status exam) score.
In addition, vinpocetine’s therapeutic potential in hearing trouble is of interest. In one study, vinpocetine was given to fifty patients with chronic neurosensory hearing loss, and at least 80% experienced reduced tympanophonia. More elaborate clinical trials are warranted.
Most of the current research on vinpocetine is being carried out in Russia and Eastern Europe. The standard dose used in these studies is 15 to 45 milligrams of Vinpocetine daily.